Daily non-political popular news in brief.

Biologic treatment for rheumatoid arthritis and the risk of cancer

Findings of various clinical trials and observational studies conflict over the risk of malignancy related to the use of tumor necrosis factor alpha blockers.

Read more »

Keywords: biologic, treatment, rheumatoid, arthritis, risk, cancer, arthriti

« Previous | Next »

Similar news on "Biologic treatment for rheumatoid arthritis and the risk of cancer":

1. Disability from long-term rheumatoid arthritis reduced with biologic treatment
   06-12-2007 · EurekAlert!
   New data demonstrating the safety and efficacy of Enbrel (etanercept) in the treatment of rheumatoid arthritis (RA) patients over the long-term were presented today at the EULAR (European League Against Rheumatism) congress (1). Over 2,000 patients receiving this biologic treatment for up to nine years, saw improvements in disability whilst safety was also sustained over the long-term.
   Similar news · Read more »
   
2. TNF-alpha antagonist stops inflammation-induced colon cancer in its tracks
   01-24-2008 · EurekAlert!
   Individuals with the inflammatory bowel disease ulcerative colitis are at increased risk of developing colon cancer. New data have identified a central role for the soluble factor TNF-alpha in the development of colon cancer in mice induced to have inflammatory bowel disease. These data provide clear rationale for the idea that drugs antagonizing TNF-alpha (such as those used to treat rheumatoid arthritis) might reduce the risk of colon cancer in individuals with UC.
   Similar news · Read more »
   
3. Risk of lymphoma in rheumatoid arthritis decreased by long-term treatment with steroids
   06-14-2007 · EurekAlert!
   Two years or more of oral steroid treatment decreases the risk of rheumatoid arthritis related lymphoma, according to data presented today at EULAR 2007, the Annual European Congress of Rheumatology, in Barcelona, Spain. Furthermore, these effects were found regardless of when in the course of the disease the steroids were first administered. However, these beneficial effects were not observed if the steroids were taken for less than a two-year period.
   Similar news · Read more »
   
4. Common rheumatoid arthritis treatment shows potential for diabetes prevention
   07-10-2007 · EurekAlert!
   Fewer rheumatoid arthritis patients treated with the drug hydroxychloroquine went on to develop diabetes compared to those who never took the drug, according to a 20-plus-year University of Pittsburgh School of Medicine-led study reported today in the Journal of the American Medical Association. In addition, those using HCQ were less likely to take medications to manage diabetes after diagnosis. The study found risk declined a dramatic 77 percent after four years of HCQ treatment.
   Similar news · Read more »
   
5. A new target for the treatment of breast cancer
   01-11-2007 · EurekAlert!
   The active ingredient in a drug currently being tested to treat rheumatoid arthritis might also one day serve as an effective means of treating one of the deadliest forms of breast cancer. Berkeley Lab researchers have demonstrated that inhibiting the activity of the protease enzyme known as TACE can deprive tumor cells of a key factor needed for their proliferation. TACE is strongly present in a form of breast cancer which responds poorly to current therapies.
   Similar news · Read more »
   
6. Researchers develop criteria to detect bone mass deficiencies in children with chronic diseases
   06-06-2007 · EurekAlert!
   Pediatricians now have a practical tool to help determine whether children with chronic diseases like Crohn's, juvenile arthritis and anorexia nervosa -- or those undergoing cancer treatment -- are at increased risk for bone mass deficiencies, fracture or osteoporosis as they get older, according to a new study whose lead author is a researcher at Cincinnati Children's Hospital Medical Center.
   Similar news · Read more »
   
7. Predicting the risk of rheumatoid arthritis for early arthritis patients
   01-30-2007 · EurekAlert!
   A wealth of research supports early aggressive treatment with disease-modifying antirheumatic drugs (DMARDs) as the best course for preventing joint damage and avoiding the fate of a wheelchair. Still, the use of DMARDs, even the widely prescribed and generally safe methotrexate, brings the risk of liver damage and other serious complications.
   Similar news · Read more »
   
8. OHSU surgeon gives patients with lethal cancer reason to hope
   11-30-2006 · EurekAlert!
   Researchers in the OHSU Digestive Health Center are developing a system through which clinicians hope to more easily identify people at increased risk for the disease. Early identification allows physicians to identify malignancies sooner and begin aggressive treatment quicker. Only patients at high risk for pancreatic cancer will be monitored.
   Similar news · Read more »
   
9. Other highlights in the March 7 JNCI
   03-06-2007 · EurekAlert!
   Other highlights in the March 7 JNCI include a study showing how changes in breast density affect breast cancer risk, a new potential treatment for prostate cancer, a gene that influences the formation of benign bone tumors, and an essay on the additional health benefits of breast cancer prevention drugs.
   Similar news · Read more »
   
10. Tumors stopped from spreading to new sites
    04-05-2007 · EurekAlert!
    For several types of cancer, persistently high levels of the soluble factor TGF-beta in the blood after surgery, chemotherapy, or radiation therapy correlate with increased risk of early metastasis and a poor prognosis. Using a mouse model of breast cancer, researchers from Vanderbilt University have now generated evidence to suggest that treatment with TGF-beta inhibitors might help such patients.
    Similar news · Read more »